English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year.    Methods  Randomized controlled trials were searched by using MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The data was evaluated and statistically analyzed by using RevMan version 5.3.0.    Results  Five studies including 4348 patients were studied. The analysis found that the combination group was significantly greater effect in international prostate symptom score (mean difference [MD], − 1.43; 95% confidence interval [CI], − 2.20 to − 0.66;  P  = 0.0003), prostate volume (MD, − 10.13; 95% CI, − 12.38 to − 7.88;  P  < 0.00001), transitional zone volume (MD, − 3.18; 95% CI, − 3.57 to − 2.79;  P <0.0001), maximum urine flow rate (MD, 1.05; 95% CI, 0.82 to 1.29;  P  < 0.00001), prostate specific antigen (MD, − 0.54; 95% CI, − 0.80 to − 0.29;  P  < 0.0001) and post-void residual volume (MD, − 3.85; 95% CI, − 4.95 to − 2.76;  P  < 0.00001) compared with the tamsulosin group. In terms of safety, including adverse events (odds ratio [OR], 2.06; 95% CI, 1.34 to 3.17;  P  = 0.001), erectile dysfunction (OR, 2.24; 95% CI, 1.73 to 2.92;  P  < 0.00001), ejaculation disorder (OR, 3.37; 95% CI, 1.97 to 5.79;  P  < 0.0001), retrograde ejaculation (OR, 2.30; 95% CI, 1.08 to 4.93;  P  = 0.03), decreased libido (OR, 2.25; 95% CI, 1.53 to 3.31;  P  < 0.0001) and loss of libido (OR, 3.38; 95% CI, 1.94 to 5.88;  P <0.0001), the combination group showed poor tolerance than the tamsulosin group with the exception of dizziness (OR, 1.16; 95% CI, 0.75 to 1.80;  P  = 0.50). The combination group significantly reduced the risk of clinical progression than the tamsulosin group especially in incidence of BPH-related symptom progression (OR, 0.56; 95% CI, 0.46 to 0.67;  P  < 0.00001) and acute urinary retention (OR, 0.61; 95% CI, 0.38 to 0.98;  P  = 0.04).    Conclusion  The combination of tamsulosin plus dutasteride provides a preferable therapeutic effect for BPH with a higher incidence of sexual side effects, but combination-therapy can markedly reduce risk of BPH-related symptom progression and acute urinary retention relative to tamsulosin monotherapy.

bmc urology

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia